Plain-English translation of NCT06409585 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a new radioactive imaging dye called 68Ga-FAPI that can help doctors see scarring (fibrosis) in the heart muscle. The dye has already been used safely in cancer patients and shows promise in identifying heart scarring. Researchers will use this imaging tool to better understand several heart conditions and potentially develop new treatments that could slow or prevent heart damage.
Heart scarring is a major problem in many heart muscle diseases and can lead to heart failure, dangerous heart rhythms, and death—but doctors don't fully understand how it develops or how to treat it. This trial aims to use advanced imaging to track how scarring changes over time, which could help doctors identify which patients are at highest risk and develop new targeted therapies.
You likely qualify if…
You likely don't qualify if…
You will have a baseline visit where you'll receive an echocardiogram (ultrasound of your heart) and then a special PET-MRI scan using the new imaging dye—this combination scan allows doctors to see both the structure and activity of scarring in your heart. You'll return for follow-up tests (another echocardiogram and MRI) between 12 and 18 months later so researchers can track whether the scarring has changed. The entire study takes about a year to complete and helps doctors understand how your heart condition progresses over time.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
United Kingdom